Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23142607 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL10243854 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL22882669 | 0.85 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL2847154 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL4178623 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL7269037 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL8759612 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL20054184 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL23142610 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL19788039 | 0.81 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1284942-A | matrix metalloproteinase inhibitors | PFIZER LTD (US) | 2001-02-21 | — | — | CN | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0521827-B1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA GEIGY AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | ALDH1A1 889/4885MAPK1 4408/4885L3MBTL1 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.